Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation

Painful Diabetic Neuropathy Clinical Trial

Official title:

Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation: (QUANT) HF10 Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03769675
• Other study ID #: 17-004317
• Status: Completed
• Phase: N/A
• Start date: November 20, 2018
• Est. completion date: April 15, 2022

Study information

• Verified date: April 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Will participants with painful lower extremity diabetic peripheral neuropathy (DPN) that are treated with high frequency spinal cord stimulation (HF10 SCS) have improvements in lower extremity peripheral nerve function?

Description:

This research study is being conducted to find out if spinal cord stimulation (SCS) can improve nerve function. SCS is FDA approved for the treatment of intractable neuropathic (nerve) pain related to diabetic peripheral neuropathy. With SCS a wire is placed in the epidural space and the spinal cord is stimulated to interrupt the pain signal coming from the legs. The spinal cord stimulator is a device similar to a pacemaker (which helps treat abnormal rhythms of the heart). Recent studies have suggested that SCS with high frequencies can improve nerve function for subjects with painful peripheral neuropathy therefore, the investigators are looking to measure changes in nerve function after SCS for treatment of painful diabetic peripheral neuropathy. The purpose of this research is to gather information on the effect of high frequency spinal cord stimulation (HF10) on nerve function with a spinal cord stimulator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: April 15, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Type 2 diabetes mellitus
• Refractory predominantly lower extremity neuropathic pain for > 1 year
• Presence of length dependent peripheral neuropathy on sudomotor testing
• Completed spinal cord stimulation trial with 40% or greater pain reduction from baseline
• Failed medication trials or contraindication to gabapentin medications (gabapentin, pregabalin) and/or serotonin/norepinephrine reuptake inhibitors (tricyclic antidepressant (TCA) or duloxetine or venlafaxine)
• Average pain score on a visual analog scale (VAS) of = 5 (with 0 representing no pain and 10 the worst pain imaginable)
• Appropriate surgical candidate for spinal cord stimulator

Exclusion Criteria:

• Severe Autonomic Neuropathy as measured by the composite autonomic scoring scale (10 point scale) with a score = 7
• History of sympathectomy
• Uncontrolled arterial hypertension (Systolic Blood Pressure >160)
• Baseline Foot TcPO2 < 10 mmHg to exclude patients with severe peripheral arterial disease
• Hemoglobin A1c > 8%
• Stable opioid regimen with oral morphine equivalent = 100 mg/day
• Alternative principle cause for peripheral neuropathy or lower extremity neuropathic pain
• Disruptive psychiatric disorder (screened for during preoperative psychiatric evaluation)
• Pending litigations
• Women of child bearing potential unwilling to use contraception or found to be pregnant as part of perioperative screening
• Patients unable to hold medications that would impact autonomic testing

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Pain
• Painful Diabetic Neuropathy
• Peripheral Nervous System Diseases

Intervention

Device:
• High Frequency Spinal Cord Stimulator
The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain Assessment	Pain measurement using a Visual Analog Pain Scale by placing an X in the box to indicate the severity of pain from no pain to intolerable pain. The X in the box translates to a score of zero for no pain and increases by an additional 0.5 up to a high score of 10 which would be intolerable pain.	Baseline, 12 months
Primary	Neuropathy Symptoms and Change (NSC) Score	Validated questionnaire that evaluates change in neuropathy symptoms, including symptoms of weakness, sensory symptoms, and autonomic symptoms. Answers to questionnaire are yes/no and if yes, then degree of severity is evaluated with a plus one(slight), plus two (moderate) and plus three (severe). Questionnaire screens the presence and severity of diabetic peripheral neuropathy. Change in severity of symptoms are compared over time. Total scores range from 0 - 114, lower scores reflect no neuropathy symptoms, higher scores reflect more neuropathy symptoms.	baseline, 12 months
Primary	Oswestry Disability Index	Questionnaire examines perceived level of disability in 10 everyday activities of daily living including pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life and traveling. The 6 statements are scored from 0 to 5 scale, zero meaning no disability. The final score ranges from 0-100 with a score of 0-20 equals minimal disability, 21-40 equals moderate disability, 41-60 equals severe disability, 61-80 equals crippled and 81-100 equals bed-bound.	Baseline, 12 months
Primary	Neuropathy Impairment Score (NIS)	Subject's scores neuropathic deficits using a scale of 0-4 (zero=normal, 4=paralysis) to measure muscle weakness. The NIS score is a measure of neurologic impairment. The NIS Score has a range of 0 to 244. Lower scores indicate higher function, higher scores indicate lower function.	Baseline, 12 months
Primary	Lower Limb Function Test	Test for lower limb function in which the subject will need to walk on toes, walk on heels, and arise from kneeled position, each test is marked as not applicable, normal or abnormal. The examination assesses each component for the left and right side separately. If the test is normal, it is given a score of 0, and if it is abnormal, a score of 1. Not applicable scores a zero. Total scores range 0-6. Therefore, the maximum score of 6 indicates abnormality in all 3 components bilaterally and a minimum score of 0 indicates a normal result for all 3 components bilaterally.	Baseline, 12 months
Primary	Modified Leads Assessment of Neuropathic Symptoms and Signs	Questionnaire to identify and analyze pain by answering yes/no which translates to scores from 0-24. A score of 12 or more suggests pain of predominantly neuropathic origin.	baseline, 12 months
Primary	Positive Pain	Numeric Rating Scale used to assess pain from a scale of 0 (no pain) to 10 (worst possible pain)	baseline, 12 months
Secondary	Patient Health Questionnaire	Screens for the presence and severity of depression with 9 questions in a scale of 0-3. Zero=not at all, 1=several days, 2=more than half the days, 3=nearly every day. Total score range 0 - 27. A total score of 0-4=minimal depression, 5-9=mild depression, 10-14=moderate depression, 15-19=moderately severe depression, 20-27=severe depression	Baseline, 12 months
Secondary	Height	Subjects calculated height in centimeters.	Baseline, 12 months
Secondary	Weight	Subjects calculated weight in kilograms	Baseline, 12 months
Secondary	Body Mass Index (BMI)	Subject's BMI calculated as weight in kilograms divided by height in meters squared. Uses measurements of height and weight obtained during study (with appropriate metric conversions)	Baseline, 12 months
Secondary	Hemoglobin A1c	Hemoglobin is a protein within red blood cells. As glucose enters the bloodstream, it binds to hemoglobin, or glycates. The more glucose that enters the bloodstream, the higher the amount of glycated hemoglobin. An A1C level below 5.7 percent is considered normal. Reported as percentage of glycated hemoglobin	Baseline, 12 months
Secondary	Forearm Sweat Volume Quantitative Axon Reflex Sweat Test (Q-SWEAT)	Test that measures the rate and volume of sweat to determine the severity and pattern of autonomic disorders. As measured by µL/cm²	baseline, 12 months
Secondary	Proximal Leg Laser Doppler Flowmetry (LDF)	Laser Doppler velocimetry is used in hemodynamics research as a technique to partially quantify blood flow in human tissues such as skin. Within the clinical environment, the technology is often referred to as laser Doppler flowmetry (LDF). As measured in perfusion units (p.u.)	Baseline, 12 months
Secondary	Extensor Digitorum Brevis Muscle Nerve Conduction	A nerve conduction study (NCS) is a medical diagnostic test commonly used to evaluate the function, especially the ability of electrical conduction, of the motor and sensory nerves of the human body. As measured by amplitude (AMP) milliamp (mA)	Baseline, 12 months

External Links

•   Mayo Clinic Clinical Trials